Wall Street equity research analysts covering Rocket Pharmaceuticals (NASDAQ: RCKT) maintain an average consensus 12-month price target of approximately $8.84 to $9.60, with individual forecasts ranging from lower conservative estimates up to a high target of $15.00, reflecting optimism in its gene therapy pipeline tempered by clinical milestone risks.